Targeting HER2 for the treatment of HER2-positive cancers has been efficacious and promising for advanced or metastatic breast cancer, gastric cancer, and gastroesophageal cancer [30,37,38,39,42]. This evidence concerns the gene ERBB2 and gastric cancer.